The US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system for adults and children ages 4 years and older with diabetes. The ...
Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback